Privia Health (PRVA) Cash & Equivalents (2020 - 2026)

Privia Health's Cash & Equivalents history runs 7 years deep, the most recent figure standing at $419.5 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 10.61% year-over-year to $419.5 million in Q1 2026; TTM through Mar 2026 was $419.5 million, a 10.61% decrease from a year earlier, with the FY2025 full-year figure at $479.7 million, down 2.33% from the prior year.
• Cash & Equivalents eased to $419.5 million in Q1 2026 per PRVA's latest filing, from $479.7 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $491.1 million in Q4 2024 and bottomed at $292.2 million in Q2 2022.
• The 5-year median for Cash & Equivalents is $387.4 million (2024), against an average of $380.8 million.
• Biggest YoY gain for Cash & Equivalents was 285.57% in 2022; the steepest drop was 12.49% in 2022.
• Year by year, Cash & Equivalents stood at $348.0 million in 2022, then grew by 11.93% to $389.5 million in 2023, then grew by 26.09% to $491.1 million in 2024, then slipped by 2.33% to $479.7 million in 2025, then dropped by 12.54% to $419.5 million in 2026.
• Per Business Quant, the three latest PRVA Cash & Equivalents figures stand at $419.5 million (Q1 2026), $479.7 million (Q4 2025), and $441.4 million (Q3 2025).